Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases

Recent studies suggested a potential of rituximab (RTX) in treating autoimmune thrombocytopenia (AITP) secondary to autoimmune diseases. In this study, we retrospectively evaluated the efficacy and safety of RTX therapy in patients with refractory AITP secondary to systemic lupus erythematosus (SLE)...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Bin, Li, Ting, Guo, Li, Shen, Hao, Ye, Shuang, Chen, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539196/
https://www.ncbi.nlm.nih.gov/pubmed/26203828
http://dx.doi.org/10.1097/RHU.0000000000000273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539196/
https://www.ncbi.nlm.nih.gov/pubmed/26203828
http://dx.doi.org/10.1097/RHU.0000000000000273

Ejemplares similares